Why the study?
Although limb cooling may prevent chemotherapy-induced peripheral neuropathy, logistical challenges exist in ensuring consistent efficacy and safety, requiring validation of strict temperature control.
Does limb cooling at 13°C reduce paclitaxel-induced peripheral neuropathy in patients with breast cancer receiving perioperative paclitaxel?
Does limb cooling at 13°C reduce paclitaxel-induced peripheral neuropathy in patients with breast cancer receiving perioperative paclitaxel?
Answers are grounded in this paper and cite their sources.
This study protocol outlines a randomized controlled trial to evaluate whether a strictly temperature-controlled limb-cooling device at 13°C can effectively and safely reduce paclitaxel-induced peripheral neuropathy in breast cancer patients.
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common adverse events that can significantly impair the quality of life of patients. Although limb cooling may be beneficial for preventing CIPN, logistical challenges exist in ensuring consistent efficacy and safety. The purpose of this randomized controlled trial is to validate whether limb cooling with strict temperature control can reduce CIPN in patients with breast cancer receiving weekly paclitaxel as a perioperative treatment. Methods: intravenous infusion) as perioperative chemotherapy. Patients will be randomly divided into the intervention or control groups and undergo limb cooling therapy maintained at a constant temperature of 13°C and 25°C, respectively. The primary endpoint is the proportion of patients who report Patient Neurotoxicity Questionnaire (PNQ) ≥ D in their limbs by the end of the study treatment or at the time of discontinuation. Discussion: The results of this trial will contribute to the establishment of new evidence for limb cooling therapy in the mitigation of CIPN and present a safe and stable cooling device that may be suitable for use in the clinic. Clinical trial registration: https://jrct.niph.go.jp/en-latest-detail/jRCT2032210115, identifier jRCT2032210115.
No takes yet. Share an insight, caveat, or question.
Funasaka et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: